<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344314</url>
  </required_header>
  <id_info>
    <org_study_id>BDT-PIVCAU001</org_study_id>
    <nct_id>NCT04344314</nct_id>
  </id_info>
  <brief_title>Impact of PIVC Length and Gauge on Catheter Indwell Time</brief_title>
  <official_title>A Randomized Controlled Post-market Study to Assess the Impact of Peripheral Intravenous Catheter Length and Gauge on Catheter Indwell Duration and Haemolysis in Human Participants Using a Bilateral, Cephalic Vein Cannulation Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Griffith University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Becton, Dickinson and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, open-label, multi-visit study design, in 40 healthy participants,&#xD;
      randomized by gauge of peripheral intravenous catheter (PIVC) device into the lower arm&#xD;
      cephalic vein of both arms.&#xD;
&#xD;
      The purpose of this study is to assess impact of catheter length and gauge on PIVC indwell&#xD;
      time over a 72 hour period. This study will also evaluate the incidence of haemolysis using&#xD;
      blood draws from the PIVC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to provide preliminary information on the performance of the peripheral&#xD;
      intravenous catheter (PIVC) device,&#xD;
&#xD;
        -  assess how blood collection through different catheters over time effects device&#xD;
           performance, and&#xD;
&#xD;
        -  assess the quality of the blood that is collected through those catheters. Four&#xD;
           variations of the BD Nexiva PIVC will be used in this study. Participants will be&#xD;
           randomised by gauge of peripheral intravenous catheter (PIVC) device into the lower arm&#xD;
           cephalic vein of both arms. PIVC indwell time will be monitored up to 72 hrs (removal at&#xD;
           72 hrs or upon inability to flush/aspirate). Blood will be collected Day 1 throughout&#xD;
           the remainder of indwell time.&#xD;
&#xD;
      Each participant will complete 6 visits: a Screening Visit (V1), PIVC in situ (V2-V5) and&#xD;
      follow-up (V6).&#xD;
&#xD;
      The in-situ catheter positions will be compared to the expected tip position based on the&#xD;
      catheter lengths. Blood collected will be analysed for haemolysis.&#xD;
&#xD;
      As both device length and gauge are expected to influence haemolysis the study design enables&#xD;
      evaluation of both design features.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Actual">March 12, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised, controlled</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess patent indwell time between PIVCs of different length and gauge.</measure>
    <time_frame>72 hrs</time_frame>
    <description>Catheter indwell time for each PIVC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess haemolysis occurrence based on blood collection device, catheter device configuration</measure>
    <time_frame>72 hrs</time_frame>
    <description>Haemolysis: Frequency of occurrence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Indication for Peripheral Intravenous Catheterisation</condition>
  <arm_group>
    <arm_group_label>Small gauge arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 PIVCs of same gauge and different lengths</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Large gauge arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>2 PIVCs of same gauge and different lengths</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral Intravenous Catheter</intervention_name>
    <description>Randomised controlled</description>
    <arm_group_label>Large gauge arm</arm_group_label>
    <arm_group_label>Small gauge arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or Male&#xD;
&#xD;
          -  18-65 years of age&#xD;
&#xD;
          -  Not pregnant at time of recruitment within 48 hrs Day 1 procedures (self-reported)&#xD;
&#xD;
          -  Normal coagulation results (prothrombin time 13-17 sec; activated partial&#xD;
             thromboplastin time 27-37 sec)&#xD;
&#xD;
          -  Normal platelet aggregation results for ADP, TRAP, and collagen induced maximal&#xD;
             amplitude (&gt;70% amplitude over 6 mins)&#xD;
&#xD;
          -  Target cephalic veins readily cannulatable (i.e., ≥ ~2.55 mm to obtain C/V ratio less&#xD;
             than 45% as indicated by standard 52 of the INS guidelines&#xD;
&#xD;
          -  Able and willing to provide verbal and written consent&#xD;
&#xD;
          -  Must be an Australian citizen with current Medicare card&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of pro coagulative state/condition (e.g. previous deep vein thrombosis&#xD;
&#xD;
          -  Current hypertension (e.g., systolic &gt;139 OR diastolic &gt;89 mmHg)&#xD;
&#xD;
          -  Currently on any anti-coagulant or platelet inhibitor medication. Use of NSAIDs and&#xD;
             aspirin will be documented however not exclusionary.&#xD;
&#xD;
          -  Hemophilia or any current or history of bleeding disorder or tendency&#xD;
&#xD;
          -  Presence or report of current blood borne disease/infection (e.g. hepatitis, HIV,&#xD;
             leukemia, lymphoma)&#xD;
&#xD;
          -  Difficult vascular access (i.e., vein must be readily palpable and cannulatable - no&#xD;
             less than ~2.55 mm diameter to maintain ≤45% C/V ratio) as indicated by standard 52 of&#xD;
             the INS guidelines&#xD;
&#xD;
          -  Allergy or sensitivity to chlorhexidine gluconate, isopropyl alcohol, latex, or skin&#xD;
             adhesives&#xD;
&#xD;
          -  BMI &lt;18.5 kg/m2 or ≥35 kg/m2&#xD;
&#xD;
          -  Positive results for the urine drug screen at screening or check-in (including&#xD;
             opiates, methadone, cocaine, amphetamines)&#xD;
&#xD;
          -  History or presence of alcoholism (self-reported) or drug abuse within the past 2&#xD;
             years&#xD;
&#xD;
          -  A current or previous medical, physical, mental/cognitive disorders or anatomical&#xD;
             conditions that, in the opinion of the investigator, would place the patient at risk,&#xD;
             would make them unable to perform study procedures or has the potential to confound&#xD;
             interpretation of the study results. (e.g., musculo-skeletal injury, chronic back&#xD;
             pain)&#xD;
&#xD;
          -  Employed by Becton Dickinson, Teleflex Medical, Smiths Medical or B Braun (conflict of&#xD;
             interest)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Griffith University</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <zip>4111</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 7, 2020</study_first_submitted>
  <study_first_submitted_qc>April 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

